ferric carboxymaltose
Jump to navigation
Jump to search
Indications
- intravenous iron replacement for iron-deficiency
- reduces hospitalization burden in stabilized, iron-deficient patients with heart failure due to LV systolic dysfunction[1][3]
Adverse effects
- transient hypophosphatemia*[2]
* due to increased FGF23 causing phosphaturia & a decrease in formation of calcitriol[2]
More general terms
References
- ↑ 1.0 1.1 Ponikowski P et al. on behalf of the AFFIRM-AHF Investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial. Lancet 2020 Nov 13; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33197395 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32339-4/fulltext
- ↑ 2.0 2.1 2.2 Medical Knowledge Self Assessment Program (MKSAP) 19. American College of Physicians, Philadelphia 2021
- ↑ 3.0 3.1 Ponikowski P, Mentz RJ, Hernandez AF et al. Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J. 2023 Aug 26:ehad586 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37632415 https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehad586/7251520